{
  "kind": "treatment",
  "slug": "dextromethorphan-bupropion-auvelity",
  "type": "antidepressant",
  "name": "Dextromethorphan-Bupropion (Auvelity)",
  "summary": "A combination medication approved for the treatment of major depressive disorder, combining NMDA receptor antagonism and norepinephrine-dopamine reuptake inhibition.",
  "description": "Auvelity is an oral combination of dextromethorphan hydrobromide and bupropion hydrochloride. Dextromethorphan acts as an NMDA receptor antagonist, sigma-1 receptor agonist, and serotonin reuptake inhibitor, while bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) and CYP2D6 inhibitor, prolonging dextromethorphan's half-life. This combination provides a novel mechanism for treating major depressive disorder (MDD) and offers a rapid onset of antidepressant effects.",
  "category": "medications/antidepressants",
  "tags": [
    "nmda-antagonist",
    "ndri",
    "mdd",
    "antidepressant",
    "combination"
  ],
  "metadata": {
    "drug_classes": [
      "NMDA Receptor Antagonist",
      "Norepinephrine-Dopamine Reuptake Inhibitor",
      "Combination Product"
    ],
    "therapeutic_categories": [
      "Depression",
      "Mood Disorders"
    ],
    "mechanism_categories": [
      "Dopamine Blocker"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": false,
    "brand_names": [
      "Auvelity"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "Not assigned",
    "age_groups": [
      "Adult"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Primary Care"
    ],
    "fda_approval_year": 2022
  },
  "clinical_metadata": {
    "primary_indications": [
      "Depression"
    ],
    "off_label_uses": [
      "Potential use in treatment-resistant depression",
      "Neuropathic pain (research)"
    ],
    "contraindications": [
      "Seizure disorders",
      "Eating disorders (bulimia/anorexia)",
      "Abrupt discontinuation of alcohol or sedatives",
      "MAOI use within 14 days",
      "Severe hepatic impairment"
    ],
    "monitoring_required": [
      "Mood and suicidality",
      "Blood pressure",
      "Signs of serotonin syndrome",
      "Seizure risk"
    ],
    "efficacy_rating": {
      "depression": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "auvelity",
      "dextromethorphan bupropion",
      "nmda antagonist antidepressant",
      "mdd combination treatment"
    ],
    "synonyms": [
      "dextromethorphan hydrobromide and bupropion hydrochloride"
    ],
    "common_misspellings": [
      "auveliti",
      "avelity"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Major Depressive Disorder (MDD) in adults"
      ]
    },
    {
      "type": "mechanism",
      "text": "Dextromethorphan is an uncompetitive NMDA receptor antagonist, sigma-1 receptor agonist, and serotonin reuptake inhibitor. Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) and potent CYP2D6 inhibitor, which increases dextromethorphan exposure by slowing its metabolism."
    },
    {
      "type": "dosing",
      "adult": {
        "mdd": "Start with 45 mg dextromethorphan / 105 mg bupropion once daily in the morning for 3 days, then increase to twice daily (morning and afternoon) at least 8 hours apart."
      },
      "geriatric": "Use with caution; no specific adjustments unless renal/hepatic impairment present",
      "hepatic_impairment": "Avoid in severe impairment; use with caution in mild/moderate",
      "renal_impairment": "Use with caution; monitor closely in severe impairment"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Extended-release tablets: 45 mg dextromethorphan hydrobromide / 105 mg bupropion hydrochloride"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Clinical improvement may be observed within 1â€“2 weeks, with some patients noting benefit within days."
    },
    {
      "type": "adverse_effects",
      "common": [
        "dizziness",
        "headache",
        "diarrhea",
        "somnolence",
        "dry mouth",
        "insomnia"
      ],
      "less_common": [
        "anxiety",
        "tremor",
        "palpitations",
        "constipation"
      ],
      "serious": [
        "seizures",
        "serotonin syndrome",
        "hypertension",
        "manic episodes in bipolar disorder"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults.",
      "other": [
        "Seizure risk increases with higher doses or predisposing conditions",
        "Monitor for serotonin syndrome with serotonergic drugs",
        "May cause increases in blood pressure"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "MAOIs",
          "risk": "Serotonin syndrome/hypertensive crisis",
          "action": "Contraindicated; 14-day washout"
        },
        {
          "with": "Other serotonergic drugs",
          "risk": "Serotonin syndrome",
          "action": "Monitor closely"
        },
        {
          "with": "Drugs lowering seizure threshold",
          "risk": "Increased seizure risk",
          "action": "Avoid if possible"
        },
        {
          "with": "CYP2D6 substrates",
          "risk": "Increased levels of substrate",
          "action": "Consider dose adjustments"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Mood and suicidality",
        "Blood pressure",
        "Signs of serotonin syndrome",
        "Neurological status for seizure activity"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Limited human data; use only if benefits outweigh risks",
      "lactation": "Unknown if excreted in breast milk; caution advised",
      "pediatrics": "Not approved under 18 years",
      "geriatrics": "Monitor for increased sensitivity to adverse effects"
    },
    {
      "type": "tapering",
      "text": "No specific taper required, but consider gradual reduction to minimize withdrawal from bupropion component."
    },
    {
      "type": "clinical_notes",
      "items": [
        "One of the first oral NMDA receptor antagonists approved for depression",
        "May offer faster onset than traditional antidepressants",
        "Should not be used in combination with other bupropion-containing products"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Auvelity Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "Clinical Trial Data on Auvelity",
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Dextromethorphan-Bupropion (Auvelity): Rapid-Onset Antidepressant",
    "description": "Auvelity combines dextromethorphan and bupropion for MDD treatment, offering NMDA antagonism and norepinephrine-dopamine reuptake inhibition."
  }
}
